Latest From RiKen Institute
The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.
RiKen gets $9.3m up front plus potential milestones and royalties for use of its aAVC technology, while retaining research rights to the platform. JW Pharmaceutical acquires Vietnam’s Euvipharm.
Researchers in Japan have "dosed" the initial patient in the world's first clinical trial involving a regenerative therapy based on the country's flagship induced pluripotent stem (iPS) cell technology.
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced December 2013 through January 2014.